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In the bone marrow (BM), hematopoietic stem and progenitor cells (HSPCs) reside in specialized niches near
osteoblast cells at the endosteum. HSPCs that egress to peripheral blood are widely used for transplant, and
mobilization is most commonly performed with recombinant human granulocyte colony-stimulating factor
(G-CSF). However, the cellular targets of G-CSF that initiate the mobilization cascade and bone remodeling are
not completely understood. Here, we examined whether T and B lymphocytes modulate the bone niche and
inﬂuence HSPC mobilization. We used T and B defective mice to show that G-CSFeinduced mobilization of
HSPCs correlated with B lymphocytes but poorly with T lymphocytes. In addition, we found that defective
B lymphocytes prevent G-CSFemediated osteoblast disruption, and further study showed BM osteoblasts
were reduced coincident with mobilization, induced by elevated expression of dickkopf1 of BM B lympho-
cytes. BM T cells were also involved in G-CSFeinduced osteoclast activation by regulating the Receptor
Activator of Nuclear Factor-k B Ligand/Osteoprotegerin (RANKL/OPG) axis. These data provide evidence that
BM B and T lymphocytes play a role in G-CSFeinduced HSPC mobilization by regulating bone remodeling.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Most hematopoietic stem and progenitor cells (HSPCs)
reside in the bonemarrow (BM) surrounded by a specialized,
bone-shielded environment called the bone niche, which
provides a favorable habitat for HSPC maintenance and
development [1,2]. The bone niche is composed primarily of
osteoblasts and osteoclasts, which express numerous adhe-
sion molecules and produce supportive cytokines, chemo-
kines, and other bioactive molecules essential for HSPC
retention within the BM [3,4]. In steady-state conditions,edgments on page 1390.
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ty for Blood and Marrow Transplantation.only low levels of HSPCs egress to the circulation; however,
agents with distinct cellular targets, including hematopoietic
growth factors, cytokines, and chemokines, can enhance
HSPC trafﬁcking to peripheral blood (PB), a process termed
mobilization [3,5].
Among the numerous mobilization agents, granulocyte
colony-stimulating factor (G-CSF) is widely used clinically for
HSPC mobilization [3]. G-CSFeinduced HSPC mobilization is
a complex biological process likely mediated by several
mechanisms, resulting in endosteal niche attenuation and
HSPC egress to the periphery [6]. Previous studies showed
that during HSPC mobilization, activation of proteolytic en-
zymes disrupts the stromal cell-derived factor-1eC-X-C
chemokine receptor type 4 (SDF1-CXCR4) chemotactic axis,
releases soluble Kit-ligands, and inactivates vascular cell
adhesive molecule-1, ultimately leading to HSPC egression
[7,8]. However, transgenic mice, which lack 1 or more he-




Mouse b-actin forward CACTTGAAGGGTGGAGC
Mouseb-actin reverse GGGCTAAGCAGTTGGTG
Mouse SDF-1 forward GAGCCAACGTCAAGCATCTG
Mouse SDF-1 reverse CGGGTCAATGCACACTTGTC
Mouse osteocalcin forward TCTCTCTGCTCACTCTGCTGGCC
Mouse osteocalcin reverse TTTGTCAGACTCAGGGCCGC
Mouse OPN forward GACCATGAGATTGGCAGTGATTT
Mouse OPN reverse GATCTGGGTGCAGGCTGTAAAG
Human GAPDH forward GAAGGTGAAGGTCGGAGTC
Human GAPDH reverse GAAGATGGTGATGGGATTTC
Human OPG forward CGTCAAGCAGGAGTGCAATC
Human OPG reverse CCAGCTTGCACCACTCCAA
Human RANKL forward GTCTGCAGCGTCGCCCTGTT
Human RANKL reverse ACCATGAGCCATCCACCATCGC
Human Dkk1 forward CCT TGGATGGGTATTCCAGA
Human Dkk1 reverse CCT GAGGCACAGTCTGATGA
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these proteases remains unclear.
Recently, we and others demonstrated amarked and rapid
retraction of osteoblasts in the trabecular bone area during
G-CSFeinduced HSPC mobilization [3,10]. Our data also
suggested that interrupting the balance of bone remodeling
could facilitate HSPC mobilization (unpublished data).
However, the cellular targets of G-CSF that initiate the un-
balanced bone remodeling have not been identiﬁed. Previous
studies showed the retraction of osteoblasts is at least partly
mediated through sympathetic nervous system signaling
[11,12]. Moreover, during G-CSF mobilization, loss of BM
macrophages initiates a cellular cascade that ultimately col-
lapses the bone niche environment through loss of endosteal
osteoblasts and subsequently egress of HSPC into the blood
[13-15]. In addition to monocytes/macrophages, G-CSF
administration leading to neutrophil expansion suppresses
osteoblasts and impairs the production of HSPC retention
factors such as SDF-1, stem cell factor (SCF), and vascular cell
adhesive molecule-1, thus disrupting the BM niche and
resulting in HSPC mobilization [16]. However, because
G-CSFeinduced HSPC mobilization is only partially reduced
in monocyte/macrophage-depleted mice and inhibition of
reactive oxygen species (ROS) production in neutrophils also
only partially reduces osteolineage cell apoptosis, it is likely
that G-CSF also acts on other contributing cell types.
The fact that both T and B lymphocytes express G-CSF
receptor (G-CSFR) suggests that lymphocytes may be
involved in G-CSFeinduced HSPC mobilization [3]. In this
study, we demonstrate that both T and B lymphocytes
contribute signiﬁcantly to G-CSFeinduced mobilization of
HSPCs by inﬂuencing bone remodeling.
METHODS
Patients Sample Collection
BM samples were obtained from 10 healthy donors undergoing
mobilization for allogeneic transplantation before (steady state) or 4 to 6
hours after administration (mobilized state) of recombinant human G-CSF
(5 mg/kg/day, twice a day, Filgrastim; Kyowa Hakko Kirin, Chiyoda, Tokyo,
Japan) for 3 to 5 days.
Mouse In Vivo Treatment
The mouse strains B6.129-Cd3etm1Lov/J and B6.129P2(C)-Cd19tm1(cre)Cgn/J
(6 to 8 weeks old) were obtained from the Jackson Laboratory (Bar Harbor,
ME). Homozygous mice were obtained by breeding heterozygous mice with
the mutated allele. C57BL/6 mice (6 to 8 weeks old) were from the Institute
of Laboratory Animal Science, Chinese Academy of Medical Sciences and
Peking Union Medical College (Beijing, China).
Mice were housed in sterilized microisolator cages and received auto-
claved food and water. For G-CSF mobilization, mice were injected
intraperitoneally with recombinant human G-CSF (Filgrastim) at a dose of
50 mg/day for 3 or 5 consecutive days. All mice were killed 4 to 6 hours after
the last injection. Their PB were collected from tails or eyeballs into
Microtainer tubes (Becton Dickinson, Franklin Lakes, NJ) containing EDTA,
and their bones were ﬁxed for histological examination or ﬂushed with PBS
to obtain live BM cells or ﬂushed with TRIzol reagent (Invitrogen, Carlsbad,
CA) for osteoblast RNA extraction. The experiments were repeated at least
three times. All animal handling and experimental procedures were
approved by the Animal Care and Use Committee of the Chinese Academy of
Medical Sciences and Peking Union Medical College.
Complete Blood Count
The numbers of various blood cells were counted using a pocH-100i
hemocytometer (Sysmex, Kobe, Japan) and expressed as 109/L.
Flow Cytometry
PB was collected from tails into Microtainer tubes containing EDTA.
After diluted 1:1 with PBS, PB and BM samples was incubated with FITC-
conjugated mouse lineage antibody cocktail (BioLegend, San Diego, CA,
USA) together with APC-conjugated Sca-1 (eBioscience, San Diego, CA, USA)
antibody and PE-conjugated c-kit antibody (eBioscience) to determine thelevels of LinSca-1þc-kitþ (LSK) stem cells in PB and BM. All data were
analyzed by FlowJo software (Treestar, Ashland, OR).
For lymphocyte sorting, BM was isolated from EDTA anticoagulant of
healthy donors using Ficoll-Hypaque density gradient centrifugation.
Mononuclear cells were stained with FITC anti-human CD3 and PE anti-
human CD19 antibodies (eBioscience, San Diego, CA). A FACS AriaII (BD
Biosciences, San Jose, CA, USA) was used for sorting. Cells were directly
sorted into different tubes and lysed for gene expression and Western blot
analysis.
Colony-Forming Cell Assay
Blood and BM from mice were obtained as mentioned above and the
number of nucleated cells in these tissues quantiﬁed. Nucleated cells 1.0 
104 were planted in 2.5 mL methylcellulose media supplemented with a
cocktail of recombinant cytokines (MethoCult 3434; StemCell Technologies,
Vancouver, BC, Canada). Cultures were plated in duplicate and placed in a
humidiﬁed chamber with 5% CO2 at 37C. Colonies containing at least
50 cells were counted on day 12 of culture.
Measurement of Mouse Serum Osteocalcin and TRACP-5b Level
Osteocalcin and TRACP-5b concentration were quantiﬁed by the mouse
osteocalcin and TRACP-5b ELISA kit (Bioassay Technology Laboratory,
Shanghai, China) according to the manufacturer’s instructions. The con-
centrations of osteocalcin and TRACP-5b for each sample were calculated
and expressed as average of 3 identically designed experiments.
RNA Isolation, Reverse Transcription, and Real-Time Quantitative PCR
Mouse marrow-depleted bones were ﬂushed with a total of 1 mL TRIzol
reagent and crushed in TRIzol. Total RNA of bones and sorted lymphocytes
were isolated based on the protocol provided by the manufacturer and
reverse transcribed into cDNA using the Superscript First-Strand Synthesis
System (Invitrogen) following the manufacturer’s instruction. Real-time
quantitative PCR for SDF-1, osteocalcin, and osteopontin expression were
performed on the ABI 7500 Sequence Detection System (Applied Bio-
systems, Foster, CA) in 20-mL PCR systems containing 10 mL Power SYBR1
Green PCR Master mix (Applied Biosystems), .5 mL of each primer pair (100
mM), 1 mL cDNA (40 ng RNA), and 8 mL ddH2O at the following conditions:
15 minutes of an initial denaturation at 95C followed by 40 cycles of 15
seconds at 95C and 1 minute at 60C. PCR primer sequences are shown in
Table 1. Relative expressionwas calculated as the difference (DDCT) between
the DCT values of the test sample and of the endogenous control (beta-actin
and GAPDH).
TRAP Staining
Mouse femurs were ﬁxed (4% formaldehyde in PBS, 48 hours), decal-
ciﬁed (10% EDTA, pH 7.5, 14 days), and embedded in parafﬁn. Sections (4 mm)
were deparafﬁnized, rehydrated, and stained for TRAP activity (Sigma;
Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer’s
instructions.
Immunohistochemistry
Rabbit anti-osteocalcin polyclonal antibody FL-95 (1:300; Santa Cruz
Biotechnology, Inc., Texas, USA) was used to stain mouse osteoblasts by
streptavidin-peroxidase method.
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Total proteins of donor lymphocytes were extracted and separated by
SDS-PAGE. Protein bands were detected using ECL Western blotting detec-
tion kit (GE Healthcare, Beijing, China). For Western blotting analysis, the
antibodies were diluted at 1:1000 for anti-RANKL antibody (Abcam, Cam-
bridge, MA, USA), anti-OPG antibody (Sigma-Aldrich, St Louis, MO, USA), and
anti-Dickkopf-related protein 1 (Dkk1) (Abcam, Cambridge, MA, USA) anti-
body and 1:5000 for GAPDH (Cell Signaling Technology, Inc. Danvers, USA).Statistical Analysis
The statistical signiﬁcance of overall differences among multiple groups
was analyzed by the ordinary analysis of variance using SPSS 15.0 (IBM,
Chicago, IL, USA). Data are presented as means  standard error of the mean
SEM. Data were analyzed using the nonparametric Mann-Whitney test as
appropriate for the data set. P < .05 was considered signiﬁcant.RESULTS
Reduced Mobilization in Mice with Defective B
Lymphocytes but Not Defective T Lymphocytes
It is reported that G-CSFR not only is expressed on neu-
trophils and monocytes/macrophages but also on T and B
lymphocytes, and it is likely that 1 or more of these cell types
participate in G-CSFeinduced HSPC mobilization. To further
deﬁne the role of lymphocytes in G-CSFeinduced HSPC
mobilization, we evaluated HSPC number and function in
lymphocytes of defective mice. B6.129-Cd3etm1Lov/J and
B6.129P2(C)-Cd19tm1(cre)Cgn/Jmice have defective T and B cell
function, respectively, whereas the number of total WBCs
and the percentage of LSK stem cells or colony-forming cells
of these 2 kinds of mice were similar to their wild-type
counterparts, C57BL/6 mice (Figure 1, day 0), in steady state.
In C57BL/6 and B6.129-Cd3etm1Lov/J mice, G-CSF admin-
istration induced robust mobilization of LSK cells enriched
for multipotent progenitor cells. WBCs were signiﬁcantly
increased from day 0 to day 5 (Figure 1A), and G-CSFFigure 1. Reduced mobilization in mice with defective B lymphocytes but not wit
B6.129-Cd3etm1Lov/J (black), and B6.129P2(C)-Cd19tm1(cre)Cgn/Jmice (gray) treated with G
stem cells in PB of C57BL/6 (ﬁlled circle), B6.129-Cd3etm1Lov/J (ﬁlled square), and B6.129P
each time point). Data are mean  SEM. (C) Representative scatter plots showing LSK
B6.129P2(C)-Cd19tm1(cre)Cgn/Jmice (ﬁlled triangle) during G-CSF mobilization (n ¼ 5 to 7
C57BL/6 (white), B6.129-Cd3etm1Lov/J (black), and B6.129P2(C)-Cd19tm1(cre)Cgn/Jmice (gr
mouse BM, C57BL/6 (white), B6.129-Cd3etm1Lov/J (black), and B6.129P2(C)-Cd19tm1(cre)treatment increased the percentage of LSK stem cells from
.017%  .005% on day 0, .06%  .01% on day 3, to .18%  .02%
on day 5 in C57BL/6 mice and from .014%  .001% on day 0,
.06%  .01% on day 3, to .16%  .03% on day 5 in
B6.129-Cd3etm1Lov/Jmice (Figure 1B, Supplemental Figure 1),
as well as the colony-forming cells in mouse PB (Figure 1D).
However, in B6.129P2(C)-Cd19tm1(cre)Cgn/J mice, WBCs, cir-
culation LSK, and colony-forming cells were signiﬁcantly
lower than in C57BL/6 mice (Figure 1A,B,D). The percentage
of PB LSK stem cells were .018% .001% on day 0, .02% .01%
on day 3, and .07%  .02% on day 5 in B6.129P2(C)-
Cd19tm1(cre)Cgn/J mice (Figure 1B, Supplemental Figure 1).
Although G-CSFeinduced mobilization was reduced in
B6.129P2(C)-Cd19tm1(cre)Cgn/Jmice, lymphocyte defection did
not affect the increase in LSK and colony-forming cells in the
BM normally observed in response to G-CSF (Figure 1C,E,
Supplemental Figure 2). These results suggest that the B
lymphocytes may be required for G-CSFeinduced HSPC
mobilization, whereas T lymphocytes may not be involved.Defective B Lymphocytes Prevent G-CSFeMediated
Osteoblast Disruption
Multipotent HSPCs are localized in proximity to
osteoblast-enriched endosteal regions within the BM [2].
Our previous research showed that short-term G-CSF
treatment interrupted the balance of bone remodeling in
both human and mouse models. Decreased osteoblast
numbers lead to reduced HSPC mobilization regulators,
such as SDF-1, SCF, and osteopontin, and subsequently
result in stem cell mobilization [10]. To examine the role of
lymphocyte in G-CSF mediated bone remodeling, we
detected osteolineage cells in the BM of G-CSF treated
mouse models.h defective T lymphocytes. (A) Total WBC counts in PB of C57BL/6 (white),
-CSF (n ¼ 5 to 7 each time point). (B) Representative scatter plots showing LSK
2(C)-Cd19tm1(cre)Cgn/Jmice (ﬁlled triangle) during G-CSF mobilization (n ¼ 5 to 7
stem cells in BM of C57BL/6 (ﬁlled circle), B6.129-Cd3etm1Lov/J (ﬁlled square), and
each time point). Data are mean  SEM. (D) Colony-forming cells in mouse PB,
ay), treated with G-CSF (n ¼ 5 to 7 each time point). (E) Colony-forming cells in
Cgn/J mice (gray), treated with G-CSF (n ¼ 5 to 7 each time point).
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blasts, as deﬁned by osteocalcin-positive endosteum cells,
was seen after 3 days treatment of G-CSF, and morphology of
the lining osteoblasts changed from cubical to ﬂat in control
C57BL/6 and B6.129-Cd3etm1Lov/J mice (Figure 2A,B). How-
ever, in B cell defective B6.129P2(C)-Cd19tm1(cre)Cgn/J mice,
the reduction of osteoblasts in response to G-CSF was
signiﬁcantly attenuated (Figure 2C). Osteocalcin mRNA
expression was sharply reduced by 40-fold and 22-fold
(Figure 2D, P ¼ .04 and .01) after 3 days treatment of G-CSF
in C57BL/6 and B6.129-Cd3etm1Lov/J mice, respectively,
whereas in B6.129P2(C)-Cd19tm1(cre)Cgn/J mice, osteocalcin
mRNA expression was reduced only by 3.5-fold (Figure 2D,
P ¼ .05). Meanwhile, a signiﬁcant decrease in serum osteo-
calcin protein was detected from 81.46  1.20 ng/mL on day
0 to 67.78  4.12 ng/mL on day 3, and to 64.00  3.41 ng/mL
on day 5 of mobilization in C57BL/6 mice (Figure 2E, P ¼ .01)
and from 74.79 4.13 ng/mL on day 0, to 60.75 2.95 ng/mL
on day 3, and to 60.96  3.41 ng/mL on day 5 in B6.129-
Cd3etm1Lov/J mice (Figure 2E, P ¼ .02). Nevertheless, there
were no obvious decreases in B6.129P2(C)-Cd19tm1(cre)Cgn/J
mice (Figure 2E, P ¼ .22).
Next, we detected whether B lymphocyte defection
affected important mobilization regulators and measured
SDF-1 and osteopontin mRNA expression in osteoblasts of
G-CSF treated mice. SDF-1 and osteopontin mRNA expres-
sion were substantially decreased in osteoblasts from G-CSF
treated C57BL/6 and T cell defective B6.129-Cd3etm1Lov/J
mice (Figure 3A,B, P ¼ .02 and .01 and P ¼ .01 and .03,
respectively) but were relatively unaffected in B cell
defective B6.129P2(C)-Cd19tm1(cre)Cgn/J mice (Figure 3C).
These results were further conﬁrmed by immune-
histochemical staining of mouse femur specimens. High
levels of SDF-1 and osteopontin proteins were clearly
detected in osteoblasts in bone endosteum regions on day
0 but not after 5 days of G-CSF-mobilization in C57BL/6 and
B6.129-Cd3etm1Lov/J mice (Figure 3D,E), whereas in
B6.129P2(C)-Cd19tm1(cre)Cgn/J mice the protein levels were
unchanged (Figure 3F). The above data indicate that B
lymphocytes but not T lymphocytes act as mediator during
G-CSFeinduced osteolineage cell suppression, thus dis-
rupting the BM niche and leading to HSPC mobilization.Figure 2. Decrease of mature osteoblast was not seen in B lymphocyte defective mice
in untreated (day 0) or G-CSF treated on day 3 and day 5 of C57BL/6 mice (A), B6.12
ﬁcation, 400. (D) Bone marrow osteocalcin mRNA expression of C57BL/6, B6.129-Cd3
mRNA relative to b-actin mRNA is shown. (n ¼ 5 to 7 each time point). (E) Serum
Cd19tm1(cre)Cgn/J mice (n ¼ 5 to 7 each time point; data are mean  SEM). (This FigurT Cells Involved in Osteoclast Activation after G-CSF
Administration
Our published data show that bone resorption decreased
for the short term, gradual increased after G-CSF adminis-
tration, and eventually reached a plateau on day 5 of G-CSF
administration, suggesting the number and activity of
osteoclasts are enhanced by G-CSF [10]. We tested the 3
mouse models simultaneously and found that compared
with C57BL/6 and B6.129P2(C)-Cd19tm1(cre)Cgn/J mice
(Figure 4A,B), the activity of osteoclast in T celledefective
B6.129-Cd3etm1Lov/Jmice increased slightly on day 5 of G-CSF
treatment (Figure 4C). The bone resorption marker serum
TRACP-5bwas then detected and increased from 47.78 1.02
U/L on day 0 to 53.38 1.26 U/L on day 5 in C57BL/6mice and
from 45.22  2.09 U/L on day 0 to 56.55  1.2 U/L on day 5 in
B6.129P2(C)-Cd19tm1(cre)Cgn/Jmice (Figure 4D, P¼ .04 and .02,
respectively); however, in B6.129-Cd3etm1Lov/J mice is only
increased from 49.32  1.3 U/L to 52.24  1.4 U/L (Figure 4D,
P ¼ .17). These results indicated that BM T lymphocytes may
play a role in G-CSFeinduced osteoclast activation during
HSPC mobilization.Wnt Antagonists Dkk1 Expressed by BM B Lymphocytes
Partially Involved in Osteoblast Inhibition
Previous studies demonstrated that Wnt antagonists
Dkk1 was readily detectable in BM B progenitor cells [17],
which is a key regulator of osteoblast differentiation.
Because G-CSF induces osteoblast inhibition by inﬂuencing
BM B lymphocytes, we evaluated whether Dkk1 produced
by BM B lymphocytes was involved in this effect. BM sam-
ples were obtained from 10 healthy donors in steady state
and mobilized state, and B lymphocytes were sorted by
FACS. We measured Dkk1 mRNA expression in B lympho-
cytes at these 2 time points. Dkk1 mRNA expression was
increased by 10-fold (Figure 5A, P ¼ .03) after 3 to 5 days of
G-CSF treatment in donors. Western blot analysis conﬁrmed
that Dkk1 was up-regulated in the mobilized state
(Figure 5B). These data link B lymphocyteeproduced Dkk1
in the destruction of HSPC niche osteoblasts in the BM in
response to G-CSF.. Representative photomicrographs showing endosteal osteoblasts (red arrows)
9-Cd3etm1Lov/J (B), and B6.129P2(C)-Cd19tm1(cre)Cgn/J mice (C). Original magni-
etm1Lov/J, and B6.129P2(C)-Cd19tm1(cre)Cgn/J mice. The expression of osteocalcin
osteocalcin concentrations of C57BL/6, B6.129-Cd3etm1Lov/J, and B6.129P2(C)-
e is available in color online at www.bbmt.org).
Figure 3. SDF-1 and osteopontin expression were unchanged in B lymphocyte defective mice. (A) BM SDF-1 and osteopontin mRNA expression of C57BL/6 mice
during G-CSF mobilization (n ¼ 5 to 7 each time point). (B) BM SDF-1 and osteopontin mRNA expression of B6.129-Cd3etm1Lov/Jmice during G-CSF mobilization (n ¼ 5
to 7 each time point). (C) BM SDF-1 and osteopontin mRNA expression of B6.129P2(C)-Cd19tm1(cre)Cgn/J mice during G-CSF mobilization (n ¼ 5 to 7 each time point).
(D) Representative photomicrographs showing immunoreactivity of SDF-1 and osteopontin in femoral metaphysial trabeculae of untreated (day 0) or G-CSFetreated
(days 3 and 5) C57BL/6 mice. Arrowheads indicate endosteal bone-lining osteoblasts. Original magniﬁcation, 400. (E) Representative photomicrographs showing
immunoreactivity of SDF-1 and osteopontin in femoral metaphysial trabeculae of B6.129-Cd3etm1Lov/J mice. Original magniﬁcation, 400. (F) Representative
photomicrographs showing immunoreactivity of SDF-1 and osteopontin in femoral metaphysial trabeculae of B6.129P2(C)-Cd19tm1(cre)Cgn/J mice. Original magniﬁ-
cation, 400.
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Potently Stimulates Osteoclast Activity during G-CSF
Mobilization
Because T cells have been shown to produce OPG and
release a soluble form of RANKL [18,19], we focused our
studies on determining the expression of RANKL and OPG in
donors during G-CSF mobilization. We measured OPG and
RANKL mRNA expression in sorted T lymphocytes in steady
state and mobilized state. RANKL mRNA expression was
increased by 5-fold (Figure 6A, P ¼ .03) after 3 to 5 days of
G-CSF treatment in donors, although there was no obvious
change of OPG mRNA level during mobilization (Figure 6B,
P ¼ .61). Western blot analysis conﬁrmed the increased
RANKL/OPG ratio (Figure 6C).
DISCUSSION
We and others have demonstrated that diminishing os-
teoblasts could lead to reduction of SDF-1 and other impor-
tant matrix components such as SCF and osteopontin,
subsequently resulting in stem cell mobilization in both
mouse and human models. However, a lack of G-CSFR
expression on osteoblasts and their progeny indicates
participation of other cells or factors [10,20]. In our previ-
ously study, we found that G-CSF induced osteoblast inhi-
bition through BM mononuclear cells (unpublished data).
Here we offer evidence that B and T lymphocytes are
required for HSPC mobilization. They induced osteoblastreduction and osteoclast activity by means of increasing
Dkk1 and RANKL/OPG ratio expression level, respectively.
These data provide a new theory of the role of lymphocytes
in the HSPC mobilization process.
Previous research has shown that BM monocytes/mac-
rophages are pivotal to maintain the endosteal niche, and the
depletion of these cells leads to the egress of HSPC mobili-
zation [13-15,21]. Although these studies suggested mono-
cyte/macrophage reduction enhances HSPCmobilization, the
magnitude of response seen after G-CSF administration is at
least 3 times more potent than macrophage depletion with
clodronate liposomes, indicating that G-CSF also acts on cells
other than monocytoid cells [14]. On the other hand, there is
a robust expansion of BM and PB neutrophil responses to
G-CSF treatment, and G-CSFR deﬁcient mice show impaired
G-CSFeinduced HSPC mobilization despite normal HSPC
number and function, indicating that neutrophils are
involved in G-CSFeinduced HSPC mobilization [16]. How-
ever, evidence also shows that the correlation between the
number of neutrophils in BM and colony-forming cells in PB
was poor during G-CSF mobilization [15].
The above studies suggest that the contribution of cellular
components to G-CSFeinduced HSPCs mobilization is still
controversial. Furthermore, most of these studies were based
on animal experiments, which are very different from those
of clinical patients. Because patients suffering from severe
immunodeﬁciency mobilize poorly with G-CSF [22], we
Figure 4. T cells involved in osteoclast activation after G-CSF administration. (A-C) TRAP staining of femoral metaphysic of untreated (day 0) and treated with G-CSF
for 5 days (day 5) in C57BL/6 (A), B6.129P2(C)-Cd19tm1(cre)Cgn/J (B), and B6.129-Cd3etm1Lov/J (C) mice. Arrowheads indicate active TRAPþ osteoclasts stained in red
(original magniﬁcation, 400). (D) TRACP-5b concentrations were analyzed by ELISA, C57BL/6 (white), B6.129P2(C)-Cd19tm1(cre)Cgn/J (black), and B6.129-Cd3etm1Lov/J
(gray) (n ¼ 5 to 7 each time point; data are mean  SEM). (This Figure is available in color online at www.bbmt.org).
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endosteal niche and sought to eliminate these populations to
evaluate their contributions to HSPC trafﬁcking. First, we
performed mobilization studies in various strains of immu-
nodeﬁcient mice that lack B or T lymphocytes. We found that
in contrast to C57BL/6 and B6.129-Cd3etm1Lov/J mice, immu-
nodeﬁcient B6.129P2(C)-Cd19tm1(cre)Cgn/J mice respond
poorly to G-CSFeinduced mobilization in that WBC counts,
circulation of LSK, and colony-forming cells were signiﬁ-
cantly lower. These results indicated that B celle but not T
celledepleted mice respond poorly to G-CSFeinduced
mobilization, consistent with the ﬁndings of Reca et al. [23],Figure 5. Wnt antagonist Dkk1 expressed by BM B lymphocytes partially involved in
B lymphocytes were detected by real-time quantitative PCR. (B) Protein levels of Dkk1
Western blotting.who used different mouse strains. Although many BM cell
populations combine together to orchestrate HSPC mobili-
zation, lymphocytes may play key roles in this proceeding.
Accumulating evidences suggest that disruption of
osteolineage niche function plays a key role in G-CSFein-
duced HSPC mobilization [10,24]. Diminishing osteoblasts
could lead to reduction of important matrix components
generated by osteoblasts such as SDF-1, SCF, and osteopontin
and subsequently causes stem cell mobilization. Mobilization
may be caused by proteolytic cleavage of niche components
as well as lower secretion due to fewer bone-forming oste-
oblasts [10]. The weakening of G-CSF mediated inhibition ofosteoblast inhibition. (A) mRNA levels of Dkk1 in steady and mobilized state
and b-catenin in steady and mobilized state B lymphocytes were detected by
Figure 6. Increased T lymphocyteeinduced RANKL/OPG ratio potently stimulates osteoclast activity during G-CSF mobilization. (A) mRNA levels of RANKL in steady
and mobilized state T lymphocytes were detected by real-time quantitative PCR. (B) mRNA levels of OPG in steady and mobilized state T lymphocytes were detected
by real-time quantitative PCR. (C) The protein levels of RANKL/OPG and b-catenin in steady and mobilized state T lymphocytes were detected by Western blotting.
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strates that B lymphocytes are involved in G-CSF mediated
endosteal niche disruption. We then analyzed osteoblast
SDF-1 and osteopontin levels in 3 mouse models and found
that compared with C57BL/6 and B6.129-Cd3etm1Lov/J mice,
B6.129P2(C)-Cd19tm1(cre)Cgn/J mice showed reduction in SDF-
1 and osteopontin. To uncover the relationship between B
lymphocyte and osteoblast inhibition, key regulator of Wnt
signaling Dkk1 was tested. Compared with steady state, B
lymphocytes produce more Dkk1 in the mobilized state,
suggesting that B lymphocytes participate in G-CSFeinduced
endosteal osteoblast inhibition. Recently, the CXCR4 antag-
onist was found to progressively replace G-CSF to mobilize
HSPCs for autologous transplants in patients who failed prior
mobilization with G-CSF [25-27]. Data showed that although
AMD3100 was effective at mobilizing HSPCs, it did not
suppress osteoblasts, endosteal cytokine expression, or
reconstitution potential of HSPCs remaining in the mobilized
BM [28]. Although the CXCR4 antagonist does not suppress
bone niche, whether it has an effect on the Dkk1 expression
of B cells during HSPC mobilization remains to be
determined.
Although previous studies indicated that osteoclasts may
contribute to osteoblast retraction by surface occupancy
during G-CSF mobilization [29,30], others showed different
results [10,13,31]. Our previous research demonstrated that
osteoblasts and osteoclasts showed different changes on day
5 of G-CSF mobilization, which interrupted the balance of
bone remodeling and eventually led to mobilization [10]. T
cell depletion in mouse models did not inﬂuence HSPC
mobilization, and the activity of osteoclasts in B6.129-
Cd3etm1Lov/J mice increased only slightly on the ﬁfth day of
G-CSF mobilization, suggesting T cells were involved in
G-CSFeinduced osteoclast activation. It is recognized that
the RANKL/OPG axis plays a key role in regulating osteo-
clastic bone resorption; in addition, the main source of
RANKL and OPG was probably from osteoblasts [32,33].
Because osteoblasts were inhibited after 3 days of G-CSF
treatment and plasma levels of sRANKL were signiﬁcantly
elevated after G-CSF administration [34], other cell compo-
nents must secrete more RANKL and stimulate osteoclasts. It
is reported that T cells produce OPG and release a soluble
form of RANKL [18,19], and we detected RANKL and OPG
expression of donor BM T cells in both steady and mobilized
states and found elevated RANKL but unchanged OPG mRNA
and protein levels. Therefore, it is possible that G-CSF mayregulate osteoclast activation via increasing RANKL/OPG
ratio expressed by BM T cells.
Taken together, our study revealed the pivotal role of B
and T lymphocytes in the process of G-CSFeinduced bone
remodeling and HSPC mobilization. G-CSF induces BM B
lymphocytes to produce more Dkk1, suppresses osteoblasts
in BM, and decreases the production of important retention
factors such as SDF-1 and osteopontin, thus disrupting the
BM niche and leading to HSPC mobilization. Because
monocytes/macrophages and neutrophils are also involved
in osteoblast ablation, it is possible that BM lymphocyte,
neutrophil, and monocyte/macrophage responses to G-CSF
simultaneously may lead to maximum HSPC mobilization.
Exploration of the cells and signals involved in G-CSFein-
duced HSPC mobilization will ultimately provide new in-
sights into how poor mobilization can be prevented and
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